Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most hepatotoxicity/monitoring statements are generally consistent with the provided label text about enzyme elevations and suspected hepatitis leading to discontinuation and further workup. However, several claims (e.g., “main concern,” “most commonly” ALT/AST, severity/risk framing, and specific recommendations/decision-making patterns) are not directly supported by the supplied prescribing information and some are phrased more assertively than the label excerpt.
Category Scores
Accurate Statements
Accutane (isotretinoin) can affect liver function.
Provided label text states clinical hepatitis has been reported and liver enzyme elevations observed during clinical trials; LFT monitoring is recommended.
Accutane may raise liver enzymes.
Provided label text: “mild to moderate elevations of liver enzymes have been observed…”
Accutane can less commonly cause more serious liver injury.
Provided label text: “Clinical hepatitis considered to be possibly or probably related…” and guidance to discontinue if hepatitis suspected.
Clinicians typically monitor liver blood tests during Accutane treatment.
Provided label text: “pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response… has been established.”
Depending on liver test results, clinicians may decide on dose changes or stopping Accutane.
Provided label text: if normalization does not readily occur or if hepatitis is suspected, “the drug should be discontinued.” (The excerpt does not explicitly endorse dose changes; it supports discontinuation when hepatitis suspected or normalization does not occur.)
If signs of liver problems occur during Accutane treatment, clinicians usually recheck labs.
Provided label text supports follow-up LFTs at weekly/biweekly intervals and discontinuation/workup if hepatitis suspected; rechecking is consistent with ongoing monitoring guidance.
If signs of liver problems occur during Accutane treatment, clinicians assess whether isotretinoin should be held or discontinued.
Provided label text: “If normalization does not readily occur or if hepatitis is suspected… the drug should be discontinued…”
Unsupported Statements
Accutane most commonly increases alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
The supplied prescribing information excerpt does not state ALT/AST, nor that these are the most common enzymes affected.
The main concern with Accutane is increases in liver enzymes found on blood work.
The provided label excerpt discusses hepatotoxicity and monitoring but does not state that liver enzyme increases are the main concern.
Clinicians may check liver function tests periodically during Accutane treatment.
While monitoring is supported, the label text specifies weekly or biweekly intervals until response is established; “periodically” is less specific and not directly stated as such.
Liver function tests during Accutane treatment are used to look for rising ALT/AST or other liver-related lab abnormalities.
The excerpt does not mention ALT/AST specifically or explicitly list what abnormalities the tests are used to detect beyond “elevations of liver enzymes” and “hepatitis suspected.”
The risk of liver test abnormalities from Accutane can be higher if the patient already has liver disease.
The provided excerpt does not state that baseline liver disease increases risk of liver test abnormalities.
The risk of liver test abnormalities from Accutane can be higher if the patient takes other substances that affect the liver.
The provided excerpt does not provide such a risk comparison statement for co-substances affecting the liver.
Heavy alcohol use can contribute to liver test abnormalities during Accutane therapy.
The provided excerpt includes an alcohol interval instruction for fasting lipids (“After consumption of alcohol, at least 36 hours should elapse…”), but does not state that heavy alcohol increases liver test abnormalities for hepatotoxicity.
Certain medications can contribute to liver test abnormalities during Accutane therapy.
The provided excerpt contains drug interactions for specific agents (vitamin A, tetracyclines, contraception-related items, St. John’s Wort, phenytoin, corticosteroids) but does not state that “certain medications” contribute to liver test abnormalities.
Clinicians should review the patient’s full medication and alcohol history before and during Accutane therapy.
The provided excerpt does not explicitly instruct to review alcohol history; it does instruct telling the doctor about all medicines in the Medication Guide, but not the combined “before and during” plus alcohol-history phrasing in this hepatotoxicity context.
Yellowing of the skin or eyes (jaundice) can be a sign of liver problems during Accutane use.
The Medication Guide excerpt lists jaundice as a symptom associated with stomach area/organ damage that includes liver, which supports it generally; however this statement is framed specifically as “a sign of liver problems during Accutane use.” The excerpt supports organ damage symptoms including liver, so this is partially supported; the excerpt does not explicitly label jaundice as “liver problems” vs “internal organ damage.” Marked unsupported due to specificity mismatch.
Dark urine can be a sign of liver problems during Accutane use.
Same specificity issue as jaundice: the Medication Guide excerpt lists dark urine under symptoms that may mean internal organs are being damaged (includes liver), but does not explicitly tie it only to liver problems.
Severe fatigue can be a sign of liver problems during Accutane use.
The supplied excerpts do not list fatigue as a sign of liver problems.
Right upper abdominal pain can be a sign of liver problems during Accutane use.
The supplied excerpts do not list right upper abdominal pain as a sign of liver problems; the Medication Guide lists severe stomach, chest or bowel pain but not RUQ specifically.
Liver enzyme elevations during Accutane treatment can occur at different points during treatment.
The provided hepatotoxicity excerpt does not describe timing variability across treatment course.
Ongoing lab monitoring for liver effects is important throughout the course of Accutane treatment rather than only at the start.
Ongoing monitoring is supported by weekly/biweekly intervals until response established, but the excerpt does not explicitly contrast “throughout vs only at the start.”
Management of Accutane liver risk usually focuses on monitoring and reducing risk factors where possible.
The excerpt supports monitoring and discontinuation if hepatitis suspected, but does not describe a “usual focus” on reducing risk factors.
Clinicians commonly adjust the dose or stop isotretinoin if liver tests worsen.
The excerpt explicitly supports discontinuation in certain scenarios (hepatitis suspected or normalization not readily occurring). It does not state that dose adjustment is common based on worsening liver tests.
Clinicians may advise limiting alcohol during isotretinoin therapy.
The provided excerpt does not advise limiting alcohol; it only mentions alcohol consumption timing for fasting lipids testing.
Clinicians may advise avoiding other liver-stressing agents during isotretinoin therapy.
The provided excerpt does not generalize to “liver-stressing agents” beyond specific drug interaction counseling present elsewhere; it does not support this generalized recommendation.
Contradictions
Important Omissions
Specific label-supported monitoring interval language: liver function tests “at weekly or biweekly intervals until the response to Accutane has been established.”
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements add specificity or stronger clinical framing (e.g., ALT/AST most common, dose changes commonly based on worsening LFTs, risk modifiers like liver disease/other substances, and alcohol/liver-stressing agent advice) that are not supported by the provided label excerpt. While the general monitoring/hepatitis/discontinuation concepts are consistent, unsupported specifics could mislead about which abnormalities are expected or how decisions are made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple hepatotoxicity statements are not directly supported by the supplied prescribing information excerpt (ALT/AST specificity, “main concern” framing, risk factor assertions, and generalized alcohol/liver-stressing agent counseling).
Suggested Improvement
Align wording to the provided label: emphasize reported clinical hepatitis possibly/probably related, mild to moderate liver enzyme elevations (~15%), discontinuation if normalization does not readily occur or hepatitis is suspected, and weekly/biweekly LFT monitoring until response established. Avoid unstated specifics (ALT/AST as most common, common dose adjustments, and general alcohol/liver-stressing agent recommendations) unless the full label text supports them.